XML 48 R29.htm IDEA: XBRL DOCUMENT v3.20.4

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Summary of Significant Accounting Policies

Schedule of disaggregation of revenue by major source

​

​	​	​	​	​	​	​
​	​	December 31,
​		2020			2019
Biopharma/Pharma	​	$	66,394	​	$	30,032
Animal Health	​		7,846	​		996
Human Reproductive Medicine	​	​	4,456	​	​	2,914
Total revenues	​	$	78,696	​	$	33,942

Schedule of geographical revenues, by origin

Given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Our geographical revenues, by origin, for the years ended December 31, 2020 and 2019, were as follows (in thousands):

​

​	​	​	​	​	​	​
​	​	December 31,
​		2020			2019
Americas	​	$	49,555	​	$	28,801
Europe, the Middle East and Africa (EMEA)	​		20,316	​		4,523
Asia Pacific (APAC)	​		8,825	​		618
Total revenues	​	$	78,696	​	$	33,942

Schedule of net loss per share

The following shows the amounts used in computing net loss per share (in thousands except per share data):

​

​	​	​	​	​	​	​
​	​	Years Ended December 31,
​		2020			2019
Net loss	​	$	(32,693)	​	$	(18,332)
Deemed dividend on Series C convertible preferred stock	​	​	(39,492)	​	​	—
Paid-in-kind dividend on Series C convertible preferred stock	​		(2,844)	​		—
Net loss attributable to common shareholders	​	$	(75,029)	​	$	(18,332)
Weighted average common shares outstanding - basic and diluted	​	​	38,582,432	​	​	33,394,285
Basic and diluted net loss per share	​	$	(1.94)	​	$	(0.55)

Schedule of number of shares excluded from the computation of diluted loss per share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

​

​	​	​	​	​
​	​	Years Ended December 31,
​		2020		2019
Stock options	​	5,920,886		3,636,806
Warrants	​	—		753,211
Series C convertible preferred stock	​	6,474,135	​	—
Convertible senior notes	​	4,810,002		—
​	​	17,205,023		4,390,017

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name:	us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration